Koninklijke Philips (NYSE:PHG) Upgraded by UBS Group to Buy Rating

Koninklijke Philips (NYSE:PHG - Get Free Report) was upgraded by investment analysts at UBS Group from a "neutral" rating to a "buy" rating in a note issued to investors on Thursday, Marketbeat reports.

Several other equities research analysts have also recently issued reports on PHG. StockNews.com cut shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a research report on Thursday, November 14th. Jefferies Financial Group upgraded Koninklijke Philips from an "underperform" rating to a "hold" rating in a research note on Tuesday, October 29th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy".

Koninklijke Philips Stock Up 1.8 %

NYSE PHG traded up $0.46 during trading hours on Thursday, hitting $26.01. 1,211,435 shares of the company were exchanged, compared to its average volume of 725,955. The company has a quick ratio of 0.74, a current ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm has a market cap of $24.44 billion, a price-to-earnings ratio of -30.96, a PEG ratio of 0.82 and a beta of 0.77. The company has a 50 day moving average of $26.25 and a two-hundred day moving average of $28.13. Koninklijke Philips has a 52-week low of $19.75 and a 52-week high of $32.91.

Koninklijke Philips (NYSE:PHG - Get Free Report) last released its earnings results on Wednesday, February 19th. The technology company reported $0.54 earnings per share for the quarter, missing analysts' consensus estimates of $0.55 by ($0.01). Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. The firm had revenue of $5.38 billion for the quarter, compared to analysts' expectations of $5.10 billion. Equities research analysts anticipate that Koninklijke Philips will post 1.63 earnings per share for the current year.

Institutional Trading of Koninklijke Philips

Institutional investors have recently modified their holdings of the stock. Creative Planning raised its stake in Koninklijke Philips by 39.3% during the 3rd quarter. Creative Planning now owns 84,263 shares of the technology company's stock worth $2,757,000 after acquiring an additional 23,768 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Koninklijke Philips by 223.8% during the third quarter. Blue Trust Inc. now owns 11,982 shares of the technology company's stock worth $392,000 after purchasing an additional 8,282 shares during the last quarter. OLD National Bancorp IN acquired a new stake in shares of Koninklijke Philips during the third quarter worth about $202,000. Allspring Global Investments Holdings LLC increased its position in shares of Koninklijke Philips by 29.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 7,347 shares of the technology company's stock worth $240,000 after purchasing an additional 1,690 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of Koninklijke Philips by 6.7% in the 3rd quarter. Signaturefd LLC now owns 28,401 shares of the technology company's stock valued at $929,000 after purchasing an additional 1,789 shares during the last quarter. Hedge funds and other institutional investors own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.